NFKB1 and Disorder of lipid metabolism: In the liver, both the NF-κB inhibitor and PPARα, down-regulated in the early stages and up-regulated in the late stages, indicating the final relief of hepatic inflammation and lipid metabolism disorder (Tyagi et al., 2011).